Dr. Bogenschutz presents quantitative findings from a psilocybin trial for alcohol use disorder, showing reduced alcohol craving and improved mood and cognition. Dr. Agin-Liebes discusses qualitative results on self-awareness and
Gabrielle Agin-Liebes
Psilocybin research journey: investigating its use for treating tobacco addiction. Includes pilot study, comparative efficacy study, and upcoming multi-site clinical trial funded by NIDA.
Psychedelic-assisted therapy's history, Bill W's admiration, and the need for peer support group understanding are discussed in relation to sobriety, recovery, and psychedelics.
Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan
Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.
Philippe Lucas
Norma Lotsof is a pioneering advocate of ibogaine treatment, working with her husband Howard Lotsof to promote its therapeutic potential worldwide, particularly in interrupting opiate addiction. Norma continues to advocate
Norma Lotsof, Lucy Walker
Study on ibogaine for methadone dependence treatment aims to establish safe detox protocol through first Phase-II trial. Weekly low-dose evaluations conducted to gather safety and efficacy data for future research.
Jose Carlos Bouso
Families of veterans are affected by trauma, depression, and addiction. Session explores healing for families impacted by veterans' struggles.
Anne Wagner, Lauren Myers, Andrea Lucie
Psychedelics show promise in treating pain and addiction. Psychedelic policy reform can inspire bipartisan coalitions and benefit drug policy reform overall.
Ethan Nadelmann
Melissa Etheridge shares her journey of addiction struggles, healing, and founding the Etheridge Foundation to research plant medicine treatments for opioid use disorder. Her mission is to provide more effective
Melissa Etheridge